{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T17:23:12Z","timestamp":1775323392905,"version":"3.50.1"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,26]],"date-time":"2020-10-26T00:00:00Z","timestamp":1603670400000},"content-version":"vor","delay-in-days":299,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine Case Reports"],"published-print":{"date-parts":[[2020]]},"DOI":"10.1016\/j.rmcr.2020.101272","type":"journal-article","created":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T22:30:33Z","timestamp":1603837833000},"page":"101272","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Nintedanib and intensive immunosuppressive therapy to treat rapidly progressive interstitial lung disease presenting anti-ARS antibodies"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2212-0631","authenticated-orcid":false,"given":"Toyoshi","family":"Yanagihara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunihiro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayaka","family":"Egashira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naruhiko","family":"Ogo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuma","family":"Asoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsukasa","family":"Nara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kensaku","family":"Takatsuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiji","family":"Yoshizawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9085-0337","authenticated-orcid":false,"given":"Sy Giin","family":"Chong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Hamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashige","family":"Maeyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmcr.2020.101272_bib1","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1067\/mjd.2002.120621","article-title":"Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sin\u00e9 myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness?","volume":"46","author":"Sontheimer","year":"2002","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.rmcr.2020.101272_bib2","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1183\/09031936.03.00026703","article-title":"Interstitial lung disease in amyopathic dermatomyositis, dermatomyositis and polymyositis","volume":"22","author":"Cottin","year":"2003","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmcr.2020.101272_bib3","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/joim.12451","article-title":"Myositis-specific autoantibodies: an important tool to support diagnosis of myositis","volume":"280","author":"Betteridge","year":"2016","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.rmcr.2020.101272_bib4","first-page":"284","article-title":"Severe respiratory failure as a presenting feature of an interstitial lung disease associated with anti-synthetase syndrome (ASS), Respir","volume":"54","author":"Piroddi","year":"2016","journal-title":"Investig"},{"key":"10.1016\/j.rmcr.2020.101272_bib5","doi-asserted-by":"crossref","first-page":"188","DOI":"10.4046\/trd.2016.79.3.188","article-title":"Acute respiratory distress syndrome as the initial clinical manifestation of an Antisynthetase syndrome","volume":"79","author":"Kim","year":"2016","journal-title":"Tuberc. Respir. Dis."},{"key":"10.1016\/j.rmcr.2020.101272_bib6","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/MCP.0000000000000698","article-title":"Insights into pathogenesis and clinical implications in myositis-associated interstitial lung diseases","volume":"26","author":"Yanagihara","year":"2020","journal-title":"Curr. Opin. Pulm. Med."},{"key":"10.1016\/j.rmcr.2020.101272_bib7","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1371\/journal.pone.0098824","article-title":"Prognostic factors for myositis-associated interstitial lung disease","volume":"9","author":"Fujisawa","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.rmcr.2020.101272_bib8","first-page":"1563","article-title":"Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis","volume":"51","author":"Gono","year":"2012","journal-title":"Rheumatol. (United Kingdom)"},{"key":"10.1016\/j.rmcr.2020.101272_bib9","first-page":"1212","article-title":"Initial predictors of poor survival in myositisassociated interstitial lung disease: a multicentre cohort of 497 patients","volume":"57","author":"Sato","year":"2018","journal-title":"Rheumatol. (United Kingdom)"},{"key":"10.1016\/j.rmcr.2020.101272_bib10","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.ejim.2013.01.002","article-title":"Clinical manifestations and outcome of anti-PL7 positive patients with antisynthetase syndrome","volume":"24","author":"Marie","year":"2013","journal-title":"Eur. J. Intern. Med."},{"key":"10.1016\/j.rmcr.2020.101272_bib11","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/MCP.0000000000000712","article-title":"Progressive fibrosing interstitial lung disease: treatable traits and therapeutic strategies","volume":"26","author":"Wongkarnjana","year":"2020","journal-title":"Curr. Opin. Pulm. Med."},{"key":"10.1016\/j.rmcr.2020.101272_bib12","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMra2005230","article-title":"Spectrum of fibrotic lung diseases","volume":"383","author":"Wijsenbeek","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmcr.2020.101272_bib13","first-page":"1900161","article-title":"INBUILD trial investigators, nintedanib in progressive fibrosing interstitial lung diseases","volume":"54","author":"Flaherty","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmcr.2020.101272_bib14","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/j.rmed.2015.07.004","article-title":"Serum cytokine profiles of patients with interstitial lung disease associated with anti-CADM-140\/MDA5 antibody positive amyopathic dermatomyositis","volume":"109","author":"Takada","year":"2015","journal-title":"Respir. Med."},{"key":"10.1016\/j.rmcr.2020.101272_bib15","article-title":"Real-world experience of nintedanib therapy in idiopathic inflammatory myopathy-related interstitial lung disease: efficacy and tolerability","author":"Liang","year":"2020","journal-title":"Res. Sq"},{"key":"10.1016\/j.rmcr.2020.101272_bib16","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00161-2019","article-title":"Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases","volume":"54","author":"Wollin","year":"2019","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmcr.2020.101272_bib17","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1124\/jpet.113.208223","article-title":"Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosiss","volume":"349","author":"Wollin","year":"2014","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.rmcr.2020.101272_bib18","series-title":"Diffus. Parenchymal Lung Dis","first-page":"PA903","article-title":"Nintedanib inhibits pro-fibrotic mediators from T cells with relevance to connective tissue disease-associated interstitial lung disease","author":"Wollin","year":"2017"}],"container-title":["Respiratory Medicine Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221300712030486X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221300712030486X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T01:07:38Z","timestamp":1761959258000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221300712030486X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":18,"alternative-id":["S221300712030486X"],"URL":"https:\/\/doi.org\/10.1016\/j.rmcr.2020.101272","relation":{},"ISSN":["2213-0071"],"issn-type":[{"value":"2213-0071","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nintedanib and intensive immunosuppressive therapy to treat rapidly progressive interstitial lung disease presenting anti-ARS antibodies","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmcr.2020.101272","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101272"}}